ResMed Analysts Increase Their Forecasts After Strong Q2 Earnings

Resmed Inc RMD reported better-than-expected earnings for the second quarter on Thursday.

The company posted quarterly earnings of $2.55 per share which beat the analyst consensus estimate of $2.46 per share. The company reported quarterly sales of $1.348 billion which beat the analyst consensus estimate of $1.321 billion.

“Our strong finish to fiscal year 2025 reflects ongoing momentum across our business, driven by robust global demand for our market-leading sleep and breathing health devices, as well as our expanding digital health ecosystem,” said Resmed’s Chairman and CEO, Mick Farrell.

ResMed shares rose 2.1% to trade at $277.70 on Friday.

These analysts made changes to their price targets on ResMed following earnings announcement.

• Piper Sandler analyst Adam Maeder maintained ResMed with a Neutral and raised the price target from $248 to $270.
• Keybanc analyst Brett Fishbin maintained the stock with an Overweight rating and raised the price target from $274 to $298.
• UBS analyst Laura Sutcliffe maintained ResMed with a Buy and boosted the price target from $285 to $325.
• RBC Capital analyst Craig Wong-Pan maintained the stock with an Outperform rating and raised the price target from $294 to $300.
• Stifel analyst Jonathan Block maintained ResMed with a Hold and boosted the price target from $240 to $270.
• Mizuho analyst Anthony Petrone maintained the stock with an Outperform rating and raised the price target from $270 to $290.

Considering buying RMD stock? Here’s what analysts think:

Read This Next:

• Wall Street’s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Photo via Shutterstock